Actualités

GSK's Specialty Medicines business is the company's primary growth driver, supported by HIV leadership, new drug launches and a deep late-stage pipeline.

AstraZeneca's oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support growth.

Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly. Pfizer wrapped fiscal 2025 with a $0.66 adjusted EPS Q4 beat. Merck followed with a Q1 2026 report dominated by a $9 billion Cidara acquisition charge. Two very different income stories for yield hunters. One Pays You to ... Pfizer vs Merck: Chasing High Yield vs Higher Returns

The United States market has shown robust performance recently, climbing 1.2% in the last week and rising an impressive 27% over the past year, with earnings expected to grow by 17% annually. In this environment, identifying stocks that may be priced below their estimated worth can offer potential opportunities for investors seeking value amidst overall market growth.

As NASA prepares to bring its hallmark space lab back to Earth, a host of private companies are emerging to fill the gap.

It is finally bouncing back after several challenging years.

The United States market has shown impressive performance, rising 1.6% over the last week and climbing 28% in the past year, with earnings forecasted to grow by 17% annually. In light of these conditions, identifying stocks that may be priced below their estimated value can offer opportunities for investors seeking potential growth at a reasonable cost.

Merck & Co., Inc. (NYSE:MRK) is one of the best inexpensive stocks to invest in right now. Merck & Co., Inc. (NYSE:MRK) announced on May 26 that its Board of Directors declared a quarterly dividend of $0.85 per share of the company’s common stock for fiscal Q3 2026, with payments set to be made on July […]

PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.

Over the last 7 days, the United States market has risen 1.6%, contributing to a 28% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of robust market performance, identifying stocks that are trading below their intrinsic value can offer investors potential opportunities for growth and value appreciation.

Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]

Merck & Co., Inc. (NYSE:MRK) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for the week. It was one of the stocks mentioned in Cramer’s game plan, as he remarked: Now Merck… Monday evening, very odd… the actual 6:00 PM, hosts a meeting to review its […]

The United States market has shown robust performance, rising 1.6% over the last week and surging 28% over the past year, with earnings forecasted to grow by 17% annually. In this environment, identifying stocks trading at significant discounts can offer potential opportunities for investors looking to capitalize on undervaluation relative to market growth expectations.

MRK wins FDA Breakthrough Therapy designation for calderasib plus Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.

CHICAGO, June 1 (Reuters) - Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir ‌available as an Ebola treatment to address the widening outbreak in ‌the Democratic Republic of Congo, a senior executive told Reuters. The outbreak, which has so far infected ​a suspected 1,100 people and resulted in 42 deaths, involves a rare strain of the virus called Bundibugyo for which there are no approved vaccines or treatments.

This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical companies, with no major plenary presentations and little data capable of moving share prices materially. But beneath the quiet surface, both AstraZeneca PLC (LSE:AZN,...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Safest Dividend Stocks to Buy Right Now. On May 22, 2026, Merck & Co., Inc. (NYSE:MRK) completed a $6 billion underwritten public offering of senior notes across multiple tranches. The issuance carried out under an existing 2010 indenture with U.S. Bank Trust National Association spans […]

Stock Market Today: The Dow Jones index rose Monday amid ongoing hopes for a U.S.-Iran deal. Nvidia stock jumped on a new chip.

AstraZeneca added to its Imfinzi armamentarium on Monday after the immuno-oncology drug led to improved survival in liver cancer patients.

The United States market has experienced a notable upswing, climbing 1.6% in the last week and rising 28% over the past year, with earnings expected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on undervalued assets.

Summit said Harmoni-6 is the first Phase 3 study to show a "statistically significant" survival advantage over a PD-1 inhibitor plus chemotherapy.

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Dividend Paying Stocks to Buy Right Now. Merck & Co., Inc. (NYSE:MRK) is one of the world’s largest healthcare companies, with a portfolio that spans prescription medicines, biologic therapies, vaccines, and animal health products. Yet much of the investment story continues to revolve around […]

The income target is straightforward: $12,500 a month equals $150,000 a year, and the portfolio doing the work is $2.8 million. Dividing the income by the capital gives the math the whole article has to solve: a blended yield of roughly 5.4%. That number falls in the middle of the income-investing spectrum, which is why ... How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier

ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.

Merck & Co. has surged past the S&P 500 Index over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.

In May 2026, Exelixis announced extensive upcoming presentations at the ASCO Annual Meeting, highlighting new CABOMETYX data and pivotal zanzalintinib trials across multiple hard-to-treat cancers. These data, alongside a new Merck collaboration on the STELLAR-316 phase 3 colorectal cancer trial using MRD-guided enrollment, underscore Exelixis’ push to extend its oncology footprint beyond CABOMETYX. We’ll now assess how this expanded zanzalintinib program, especially the STELLAR-303 and...

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.